|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2006-3-3
|
|
pubmed:abstractText |
Long-acting injectable risperidone represents the first clinically available depot atypical antipsychotic. The present study used positron emission tomography (PET) to evaluate its dopamine D(2) binding profile at doses of 25, 50, or 75 mg administered every 2 weeks.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/9-hydroxy-risperidone,
http://linkedlifedata.com/resource/pubmed/chemical/Antipsychotic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Carbon Radioisotopes,
http://linkedlifedata.com/resource/pubmed/chemical/Delayed-Action Preparations,
http://linkedlifedata.com/resource/pubmed/chemical/Isoxazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Prolactin,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidines,
http://linkedlifedata.com/resource/pubmed/chemical/Raclopride,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Dopamine D2,
http://linkedlifedata.com/resource/pubmed/chemical/Risperidone
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0002-953X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
163
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
396-401
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16513859-Adult,
pubmed-meshheading:16513859-Antipsychotic Agents,
pubmed-meshheading:16513859-Basal Ganglia Diseases,
pubmed-meshheading:16513859-Brain,
pubmed-meshheading:16513859-Carbon Radioisotopes,
pubmed-meshheading:16513859-Corpus Striatum,
pubmed-meshheading:16513859-Delayed-Action Preparations,
pubmed-meshheading:16513859-Dose-Response Relationship, Drug,
pubmed-meshheading:16513859-Drug Administration Schedule,
pubmed-meshheading:16513859-Female,
pubmed-meshheading:16513859-Humans,
pubmed-meshheading:16513859-Injections,
pubmed-meshheading:16513859-Isoxazoles,
pubmed-meshheading:16513859-Male,
pubmed-meshheading:16513859-Middle Aged,
pubmed-meshheading:16513859-Positron-Emission Tomography,
pubmed-meshheading:16513859-Prolactin,
pubmed-meshheading:16513859-Psychotic Disorders,
pubmed-meshheading:16513859-Pyrimidines,
pubmed-meshheading:16513859-Raclopride,
pubmed-meshheading:16513859-Receptors, Dopamine D2,
pubmed-meshheading:16513859-Risperidone,
pubmed-meshheading:16513859-Schizophrenia
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.
|
|
pubmed:affiliation |
Schizophrenia Program, Centre for Addiction and Mental Health, Toronto, Ont. M5T 1R8, Canada. gary_remington@camh.net
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Multicenter Study
|
